Search

everythinglearnresearchcommunity

for

Search:↓

Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.

Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.

Baricitinib was effective and safe for severe hair loss treatment over 6 months.

The niosomes effectively target hair follicles for acne treatment.

ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.

Cetuximab can cause eyelash growth, which is rare but manageable.

Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.

Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

Retinoids can change the hair growth cycle by extending the growth phase and shortening the rest phase.

New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

RU 58841 may treat acne, hair loss, and excessive hair growth.

The combination of encorafenib and binimetinib caused few skin issues.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.

The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.

Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.

Redenyl lotion effectively promotes hair growth and improves quality of life for androgenetic alopecia patients.

Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

Retinoids increase steroid sulfatase activity in leukemia cells through RARα/RXR and involves certain pathways like phosphoinositide 3-kinase and ERK-MAP kinase.

Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.

5-ARI therapy may help prevent prostate cancer progression.

Topical calcitriol is safe for preventing hair loss during chemotherapy.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.